Abstract: Triggering receptor expressed on myeloid cell-1(TREM-1) is a cell surface receptor belonging to the immunoglobulin superfamily. Its signaling pathway participates in the amplification of inflammatory response, and inhibition of its pathway can reduce inflammation level. In eye diseases, both in animal model and clinical infectious keratitis patients, the expression of TREM-1 in corneal tissues is significantly increased compared with normal cornea, which can expand the inflammatory response of keratitis, and is positively correlated with inflammatory mediators and clinical inflammation scores. Inhibition of its signaling pathway can reduce corneal inflammatory response to varying degrees, affecting the clinical prognosis of keratitis. In addition, the expression of TREM-1 was significantly increased in relevant tissues of animal models of ocular toxoplasmosis, ischemic optic neuropathy and retinal neovascular disease.TREM-1 blocker(LR12) is currently in phase II clinical trials. (Int Rev Ophthalmol, 2021, 45: 519-522)

Key words: triggering receptor expressed on myeloid cells-1, keratitis, ocular toxoplasmosis, ischemic optic neuropathy, retinal neovascularization